Organic Active Ingredients TRIZ Cases

A water-soluble host-guest complex prevents π-π stacking and quenches triplet states, protecting photosensitizers before controlled ROS generation.

PLGA microspheres adjust polymer composition to deliver progestogen linearly for 6–14 days without an initial burst or lag phase.

Seed crystals guide amlodipine mesylate monohydrate growth, limiting explosive crystallization and improving flow for direct tablet pressing.

Surgical removal and radiation leave prevention gaps; this polymorphic sodium salt is used before osteoblast-driven bone formation develops.

Blood-based FAM19A5 detection supports pre-symptomatic CNS disease diagnosis by measuring protein levels before clinical symptoms appear.

Genomic screening selects disulfiram, elesclomol, or thiram for cancers with 16q loss or low metallothionein expression.

Electrospraying converts therapeutic or diagnostic liquids into low-aggregation particles that support concentrated, low-volume dosing through standard injectors.

MFGM-rich whey protein, α-lactalbumin, phospholipids, and oligosaccharides support probiotic colonization and intestinal barrier function.

GMP-compliant lipid mixing and defined charge ratios help preserve RNA activity and product quality during extended storage.

Controlled psilocybin dosing and psychological support address limited options across anxiety, headache, and eating disorders.

Selective compounds target NLRP3 inflammasome activity to address inflammaging while limiting off-target effects and immune suppression.

Buffer and glycol or polyol cosolvents help stabilize lisdexamfetamine oral solutions against alkaline and oxidative degradation.

Composite lipid and inorganic nanoparticles protect RNA from degradation while enabling cellular delivery and in-body imaging.

Systematic substituent changes create PARG-inhibiting compounds that can increase cancer-cell sensitivity to DNA-damaging agents.

Controlled crystallization forms a five-and-a-half hydrate of treprostinil sodium salt with improved stability and reduced moisture absorption.

Formula (I) amide compounds inhibit CSF-1R to address cancer, autoimmune, and inflammatory diseases across diverse treatment contexts.

Large genetic constructs challenge viral vectors; RAFT polymer nanoparticles support tissue-directed non-viral delivery with immune evasion.

Aged tissues suppress angiogenesis as endothelial cells enlarge; ML141 stimulates YAP1 nuclear translocation to reduce cell size and restore vessel growth.

See how tetrafluorobenzyl compounds used with thrombolysis or thrombectomy target reperfusion injury and hemorrhagic transformation.

Step-up epcoritamab dosing gradually recruits T cells to CD3/CD20-positive cancer cells while limiting cytokine storm in B-NHL.

Short-lived CD73 inhibitors can require frequent dosing; optimized pharmacokinetics support parenteral intervals of up to four weeks.

Two stable solabegron zwitterion crystal forms address laboratory-scale production limits and support pharmaceutical manufacturing.

Degron-linker compounds target PTPN2 and PTPN1 for proteasomal degradation, enhancing IFNγ signaling and tumor response.

EDTANa4 binds metal ions in LABA pMDI formulations, helping limit degradation and maintain active-ingredient stability over time.

Anti-CD24 antibodies, RNAi agents, and small molecules reduce hepatic steatosis in fatty liver and obesity-related disease.

By preserving plasmin activity, chymase inhibitors accelerate fibrin clot lysis and vessel re-opening while minimizing bleeding complications.

During CPR, PEG-20k creates osmotic gradients that limit cell swelling and support coronary perfusion and organ recovery.

Replacing cyclodextrin with co-solvents, surfactants, and nanocrystal inducers supports stable posaconazole IV delivery without central venous access.

Reconstitution can hinder cyclophosphamide administration; this ready-to-use liquid approach uses solvents and antioxidants to improve storage stability.

To address inconsistent outcomes and difficult T-cell identification, the case expands neoantigen-reactive clones and selects immunogenic TCRs.

See how orally administered small RNAs target PCSK9 to lower LDL-C while addressing statin-related myalgia and hepatotoxicity.

Fluoromethyl compounds activate CaV1.2 to increase calcium current amplitude while minimizing cardiovascular side effects.

Cyclodextrin removes excess lipids while VEGF-overexpressed stem cells support neuroprotection and angiogenesis in neurodegenerative disease models.

Selected 5′ and 3′ UTR elements boost transient Cas9 or Cpf1 expression for efficient genome editing with fewer off-target effects.

Non-depletional B cell inhibition helps reduce anti-drug antibodies and rejection reactions during Barth syndrome gene therapy.

Combining HTLV-1 Gag and Env nucleic acids forms secreted virus-like particles that elicit immunity against infection.

Castor oil can make fulvestrant injections painful and require refrigeration; alternative excipients target lower irritation and 24-month stability.

Oral collagen is degraded and topical collagen cannot penetrate skin, so pyrimidine nucleotides stimulate fibroblasts through epidermal cells.

Combining anti-GD2 therapy with tipifarnib inhibits tumor-derived sEV secretion and helps restore immune activity against resistant neuroblastoma.

A multivalent DR5 agonist paired with an IAP antagonist activates complementary apoptotic pathways to overcome cancer-cell resistance.

Pyrimidine compounds use structural substitutions to treat diverse seizures while limiting motor dysfunction from disrupted neuronal balance.

A granulation and external-lubrication process forms cores with at least 70 wt% drug while supporting low friability, rapid disintegration, and smooth tablet ejection.

Glycosylation tunes hydroxytryptamine analogues for serotonin receptor modulation, addressing limited efficacy and side effects.

Replacing hydrogen with deuterium at the stereogenic center helps prevent racemization in quinazolinone piperidine diones.

Learn how a non-aqueous naloxone vehicle supports localized skin delivery while limiting naloxone N-oxide during storage.

Polar aprotic solvents such as DMA and DMSO help keep lipophilic protides soluble and stable for intravenous delivery at therapeutic doses.

Focused ultrasound transiently opens the blood-brain barrier, enabling time-point sampling to improve brain biomarker sensitivity and accuracy.

Substituent changes tune Kv3 modulators toward in vivo potency, channel selectivity, safety, and brain availability.

Conditional capacitor selection and shared-inductor switching reduce cross-regulation and dynamic power dissipation across varying loads.

Existing treatments lack effective IKKα inhibition; these compounds target the kinase to address cancer progression pathways.

Selective Nurr1:RXRα activation halts neuronal degeneration and regulates dopamine production without inducing dyskinesias associated with L-DOPA therapy.

Alpha-aminoamide derivatives target multiple neurotransmitter systems to improve cognitive symptoms while reducing side effects from dopaminergic antagonism.

A two-phase system uses lecithins and glycerol to form stable micelles without synthetic surfactants.

Merging HVJ-E immunostimulation with anti-PD-1 blockade overcomes limited monotherapy efficacy to enhance cancer cell proliferation suppression.

Controlled drospirenone formulations reduce peak plasma concentrations to improve patient tolerance while maintaining reliable contraceptive efficacy.

Removing L-menthol prevents ester degradation and skin irritation while maintaining adhesion durability.

Selective small molecule inhibitors target the nucleotide binding site of Rab7 GTPase, resolving adverse side effects from non-specific prenylation strategies.

Encapsulating berberine in heparin-chitosan nanoparticles overcomes low absorption rates, sustaining anti-IgE effects for 20 weeks.

Granulation separates gas generating agents from acid components to maintain chemical purity in effervescent formulations.

A porous polymeric matrix reversibly immobilizes an isoalloxazine-based catalyst to enhance structural stability and catalytic efficiency.

Specific PDE 7 modulators address the trade-off between therapeutic effectiveness and compound selectivity using local quality design.

Detecting UBQLN2 gene mutations enables precise identification of genetic causes in amyotrophic lateral sclerosis patients.

G-quadruplex forming modified oligonucleotides bind nucleolin on cancer cells to trigger apoptosis while minimizing toxicity to normal tissue.

Polymeric particles with urea-based peptidase inhibitors bind prostate-specific membrane antigen to deliver therapeutic agents.

Novel bicyclic diamine compounds inhibit Janus kinase activity for treating inflammatory and autoimmune disorders.

Pyrimidine-2,4-diamine derivatives inhibit EGFR and HER2 mutations to address rapid resistance development in cancer therapy.

Glycoside treprostinil derivatives reduce subcutaneous injection pain and sepsis risk while maintaining therapeutic efficacy.

KMO inhibitors reduce neuronal damage by blocking toxic metabolite formation while preserving beneficial kynurenine acid production.

Blocking CD96 binding overcomes immune suppression to enhance anti-tumor responses.

Measuring BIN1 isoform ratios enables accurate cancer diagnosis, progression tracking, and treatment efficacy assessment.

Tricyclic sulfone compounds target RORγt to reduce IL-17 levels, addressing insufficient efficacy of current autoimmune therapies.

Pyrazo-tetrahydroisoquinoline derivatives act as dopamine D1 receptor positive allosteric modulators to enhance endogenous signaling pathways.

Charged polymeric dendrimer conjugates deliver nucleic acids to myeloid cells via electrostatic interaction.

Specific particle size ranges in the crystalline PTSA salt of TGR-1202 resolve poor oral bioavailability and pharmacokinetic limitations.

Chemical Formula 1 compound promotes reelin and VEGF-C production, activating lymphatic function to reduce swelling, edema, and obesity.

Tricyclic dibenzothiazepine compounds reverse CDKL5 silencing effects on GluR2 expression and phosphorylation, addressing motor deficits in CDKL5 disorder.

A bismuth-melanin composite absorbs x-rays and gamma rays through photoelectric absorption and Compton scattering mechanisms.

Spirocyclic compounds resolve the contradiction between inhibitor efficacy and selectivity by blocking necroptosis for treating inflammatory diseases.

High-dose biotin halts disease progression in ALS by enhancing brain energy production, addressing safety concerns through intermittent dosing.

Formula I compounds acylate nucleophiles with Lewis acids to produce stereomerically pure amino acid esters, replacing hard-to-access reagents.

Formula I compound reduces viral reservoir size to address drug resistance and treatment complexity in HIV therapy.

Nanoparticulate genistein reduces pulmonary fibrosis by inhibiting NF-kB and pro-inflammatory cytokines during coronavirus infection.

Amphoteric surface modification creates a water film on PLGA microparticles, preventing mucin adsorption and enabling high-efficiency alveolar delivery.

Lipid conjugate prodrug forms a drug reservoir to sustain Entecavir release, resolving frequent dosing and food absorption trade-offs.

A piperazine derivative acts as an MC4 receptor agonist to relax the urethra and reduce residual urine volume.

Non-ionic surfactants improve bendamustine dissolution to resolve IV instability and poor oral bioavailability.

Formula I tricyclic compound targets adenosine receptors to resolve single-target limitations in treating cancer and Parkinson's disease.

Combining triiodothyronine with anti-thyroid agents induces a hypothyroid state to sensitize cancer cells.

Indazole compounds antagonize Wnt pathway activity, addressing limited therapeutic options for aberrant growth states.

7beta-alkyl orvinol analogs modulate peripheral opioid receptors to relieve pain while avoiding central sedation.

A pharmaceutical composition combining uridine monophosphate with butyrate-producing fibers to improve intestinal transit time.

Multi-arm polyethylene glycol derivatives with multiple terminal azido or alkynyl groups enable high-density click chemistry reactions.

Ischemic stimulation in 3D cultures enriches microRNAs to enhance neurogenesis while avoiding whole-cell tumor risks.

Colloidal silicon dioxide coats clopidogrel bisulfate particles to prevent sticking on metal punches and dies during compression.

Segmented yeast particles manage release timing via parameter changes, resolving the trade-off between storage stability and sustained bioavailability.